280 related articles for article (PubMed ID: 25400686)
1. The FGF/FGFR axis as a therapeutic target in breast cancer.
Brady N; Chuntova P; Bade LK; Schwertfeger KL
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):391-402. PubMed ID: 25400686
[TBL] [Abstract][Full Text] [Related]
2. The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives.
Santolla MF; Maggiolini M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081025
[TBL] [Abstract][Full Text] [Related]
3. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract][Full Text] [Related]
6. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
7. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention.
Wang Y; Liu D; Zhang T; Xia L
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802841
[TBL] [Abstract][Full Text] [Related]
8. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
10. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis.
Zhang J; Tang PMK; Zhou Y; Cheng ASL; Yu J; Kang W; To KF
Cells; 2019 Jun; 8(6):. PubMed ID: 31242658
[TBL] [Abstract][Full Text] [Related]
12. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
13. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
Pacini L; Jenks AD; Lima NC; Huang PH
Cells; 2021 May; 10(5):. PubMed ID: 34068816
[TBL] [Abstract][Full Text] [Related]
15. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Chandana SR; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
[TBL] [Abstract][Full Text] [Related]
16. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
17. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
18. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
[TBL] [Abstract][Full Text] [Related]
19. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer.
Yoshimura N; Sano H; Hashiramoto A; Yamada R; Nakajima H; Kondo M; Oka T
Clin Immunol Immunopathol; 1998 Oct; 89(1):28-34. PubMed ID: 9756721
[TBL] [Abstract][Full Text] [Related]
20. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.
McLeskey SW; Ding IY; Lippman ME; Kern FG
Cancer Res; 1994 Jan; 54(2):523-30. PubMed ID: 7506125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
